NEW YORK (GenomeWeb News) – Cancer Genetics said today it has received CLIA and New York approval to offer its microarray-based kidney cancer test.

As a result, the Rutherford, NJ-based firm has launched the test, called UroGenRA-Kidney, as part of its Kidney Complete Program. The test is intended for kidney cancer diagnosis and subtyping in its own laboratory, said Cancer Genetics, which went public in early April.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.